Quantum Cyber is the Dutch holding company that spent years selling colorectal screening kits in Europe and then discarded that franchise in a single recapitalization. David Lazar bought voting control through a two-tranche preferred placement and installed a new board around a renamed issuer. The residual claim now prices an option on licensed drone hardware rather than on a diagnostic pipeline. Continuing operations produced no revenue in the first half, so the equity is a call on whether two outside licenses and a Connecticut plant become a manufacturer before dilution closes the window.
Cash rose to $13M by June from well under $1M at year-end. Warrant exercises and the Lazar preferred supplied most of that rebuild. The same print still records an accumulated deficit of $121M and a first-half net loss of $16M. Management states that recurring losses and the absence of an established revenue source raise substantial doubt about continuity. Ordinary shares outstanding moved from about 10 million at year-end to 25 million at mid-year. A later cover count of 84 million shows how fast license shares and conversions land after the print. The public float remains a minority slice of that stack.
The next several quarters resolve whether Bridgeport and the LightShift prototype produce a funded defense order. If they do not, the $250M shelf and the Lazar preferred remain the funding path, and the public residual keeps shrinking. The last sale sits near $1 against a capitalization above $100M on zero continuing sales. That spread is the market's implied value of the licenses and the plant, not of an operating defense franchise.